Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Leqembi / lecanemab for treating early Alzheimer’s disease as of September 2025

MARA Rating Company December 16, 2025

Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over as of July 2025

MARA Rating Company December 16, 2025

Venclyxto / venetoclax for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable as of February 2022

MARA Rating Company December 16, 2025

Venclyxto / venetoclax for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable as of April 2022

MARA Rating Company December 16, 2025

Venclyxto / venetoclax for treating chronic lymphocytic leukaemia as of June 2022

MARA Rating Company December 16, 2025

Vibegron for treating symptoms of overactive bladder syndrome as of September 2024

MARA Rating Company December 16, 2025

Lupkynis / voclosporin for treating lupus nephritis as of May 2023

MARA Rating Company December 16, 2025

Vutrisiran / amvuttra for treating hereditary transthyretin-related amyloidosis as of February 2023

MARA Rating Company December 16, 2025

Brukinsa / zanubrutinib for treating Waldenstrom’s macroglobulinaemia as of October 2022

MARA Rating Company December 16, 2025

Zanubrutinib for treating chronic lymphocytic leukaemia as of November 2023

MARA Rating Company December 16, 2025